[1. Skrahina A, Hurevich H, Zalutskaya A, Sahalchyk E, Astrauko A, van Gemert W, Hoffner S, Rusovich
V. Zignol M. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir
J 2012; 39: 1425-31.10.1183/09031936.00145411]
[
2. Solovič I. Tuberkulóza, vybrané kapitoly. Vyšné Hágy, NÚTPCHaHCH 2008.]
[
3. van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, Beyers N, Van Helden PD. Classification of drugresistant
tuberculosis in an epidemic area. Lancet 2000; 356 (9223): 22-5.10.1016/S0140-6736(00)02429-6]
[
4. Rozborilová E. Tuberkulóza a mykobakteriózy. Bratislava, UK, 2009.]
[
5. van der Werf MJ, Langendam MW, Huitric E, Manissero D.Multidrug resistance after inappropriate tuberculosis
treatment: a meta-analysis. Eur Respir J 2012; 39 (6): 1511-9.10.1183/09031936.00125711]
[
6. Cegielski P, Nunn P, Kurbatova EV, Weyer K, Dalton TL, Wares DF, et al. Challenges and controversies in defining
totally drug-resistant tuberculosis. Emerg Infect Dis [Internet]. 2012 Nov [07.02.2013].]
[
7. WHO. Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency Update 2008.
WHO/HTM/TB/2008.402. Geneva, Switzerland: WHO, 2008.]
[
8. Cruz AT, Starke JR. Pediatric Tuberculosis. Pediatrics in Review 2010; 31:13-26.10.1542/pir.31.1.13]
[
9. Váňa J, Johanes R, Adamicová K, Žáček M. Zriedkavá príčina náhlej brušnej príhody. Slovenská chirurgia
2010; 7(1-2):12-4.]
[
10. Jaramillo E. Guidelines for programmatic management of drug-resistant tuberculosis. Stop TB Initiative, WHO,
2008, p. 247.]
[
11. Hopewell PC, Madhukar P, Maher D, Uplekar M, Raviglione MC. International Standards for Tuberculosis Care.
Lancet Inf Dis 2006; 6(11): 710-25.10.1016/S1473-3099(06)70628-4]
[
12. Drobac PC, Mukherjee JS, Joseph JK, MItnick C, Furin JJ, del Castillo H, Shin SS, Becerra MC. Community-
Based Therapy for Children With Multidrug-Resistant Tuberculosis. Pediatrics 2006; 117 (6): 2022-9.10.1542/peds.2005-223516740844]
[
13. Albanna AS, Menzies D. Drug-Resistant Tuberculosis: What are the Treatment Options? Drugs 2011; 71 (7):
815-25.]
[
14. Al-Dabbagh M, Lapphra K, McGloin R, Inrig K, Schaaf HS, Marais BJ, Sauve L, Kitai I, Kollmann TR. Drugresistant
tuberculosis: pediatric guidelines. Pediatr Infect Dis J 2011; 30 (6): 501-5.10.1097/INF.0b013e31820b583d21297522]
[
15. Seddon JA, Hesseling AC, Marais BJ, McIlleron H, Peloquin CA, Donald PR, Schaaf HS. Paediatric use of second-
line anti-tuberculosis agents: a review. Tuberculosis (Edinb) 2012; 92 (1): 9-17.10.1016/j.tube.2011.11.00122118883]
[
16. Porvazník I, Mokrý J, Solovič I. Actual situation in resistance to anti-tuberculotics in Slovak Republic (In
Slovak). In: Čalkovská A. (ed). Novinky v experimentálnej a klinickej medicíne. Zborník. JLFUK Martin, 2012:
152-9.]
[
17. Bartu V, Kopecka E, Havelkova M. Factors Associated with Multidrugresistant Tuberculosis: Comparison of
Patients Born Inside and Outside of the Czech Republic. The Journal of International Medical Research 2010;
38: 1156-63.10.1177/14732300100380034520819455]
[
18. WHO IUATALD. Anti-tuberculosis drug resistance in the world:third global report. Geneva: World Health
Organization, 2004: 299.]
[
19. Zignol M, Hosseini MS, Wright A, Lambregts–van Weezenbeek C, Nunn P, Watt CJ, Williams BG, Dye C. Global
incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194:479–85.10.1086/50587716845631]
